Impact of historical disease conditions on mortality and life expectancy in patients with advanced schistosomiasis in Hunan Province, China
Honglin Jiang,Jie Zhou,Xinting Cai,Benjiao Hu,Huilan Wang,Chen Fu,Ning Xu,Yanfeng Gong,Yixin Tong,Jiangfan Yin,Junhui Huang,Jiamin Wang,Qingwu Jiang,Songyue Liang,Yibiao Zhou
DOI: https://doi.org/10.1093/trstmh/trae052
2024-08-15
Abstract:Background: Although the prognosis of advanced schistosomiasis patients has significantly improved, the impact of historical disease conditions on life expectancy remains unclear. Methods: Utilizing data from an advanced schistosomiasis cohort (n=10 362) from 2008 to 2019 in Hunan, China, we examined five historical disease conditions: times of praziquantel treatment, the history of ascites, splenectomy, upper gastrointestinal bleeding (UGIB) and hepatic coma. Using latent class analysis, participants were categorized into three groups: Group 1 (characterized by no risk conditions), Group 2 (had ≤3 times of praziquantel treatment without UGIB history) and Group 3 (had UGIB history). Life expectancies were calculated using the life table method. Results: At the age of 45 y, patients with ≤3 times of praziquantel treatment, a history of ascites, UGIB, hepatic coma and those without splenectomy exhibited lower life expectancies. Groups 1, 2 and 3 had estimated life expectancies of 32.32, 26.76 and 25.38 y, respectively. Compared with Group 1, women in Group 3 experienced greater life expectancy loss than those in Group 2, with the difference narrowing with age. Conclusions: Based on the consideration of overall physical conditions, tailored treatment and healthcare, along with public health interventions targeting diverse populations, could mitigate the prevalence of poor disease conditions and premature deaths.